Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGE OTCMKTS:CURLF NYSEAMERICAN:PFNX NASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$36.86-0.1%$37.72$26.20▼$63.50$1.70B1.42463,473 shs494,212 shsCURLFCuraleaf$2.36-1.9%$2.13$0.68▼$3.65$1.61B0.781.14 million shs662,753 shsPFNXPfenex$12.75$12.75$5.26▼$14.00$437.29MN/A503,865 shsN/AVCELVericel$31.42-2.4%$36.54$30.26▼$63.00$1.62B1.33669,483 shs1.22 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics-0.05%-4.06%-1.15%-11.52%-28.26%CURLFCuraleaf-1.87%-19.73%-11.21%+185.37%-19.18%PFNXPfenex0.00%0.00%0.00%0.00%0.00%VCELVericel-2.36%-5.42%-13.40%-24.29%-31.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$36.86-0.1%$37.72$26.20▼$63.50$1.70B1.42463,473 shs494,212 shsCURLFCuraleaf$2.36-1.9%$2.13$0.68▼$3.65$1.61B0.781.14 million shs662,753 shsPFNXPfenex$12.75$12.75$5.26▼$14.00$437.29MN/A503,865 shsN/AVCELVericel$31.42-2.4%$36.54$30.26▼$63.00$1.62B1.33669,483 shs1.22 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics-0.05%-4.06%-1.15%-11.52%-28.26%CURLFCuraleaf-1.87%-19.73%-11.21%+185.37%-19.18%PFNXPfenex0.00%0.00%0.00%0.00%0.00%VCELVericel-2.36%-5.42%-13.40%-24.29%-31.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 2.88Moderate Buy$97.29163.93% UpsideCURLFCuraleaf 4.00Strong BuyN/AN/APFNXPfenex 0.00N/AN/AN/AVCELVericel 3.00Buy$60.4092.23% UpsideCurrent Analyst Ratings BreakdownLatest PFNX, CURLF, APGE, and VCEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025APGEApogee TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/28/2025APGEApogee TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$78.00 ➝ $87.008/14/2025APGEApogee TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/11/2025APGEApogee TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$90.008/8/2025CURLFCuraleafCormarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Moderate Buy8/1/2025VCELVericelCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$61.00 ➝ $58.007/7/2025APGEApogee TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/7/2025APGEApogee TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$90.007/7/2025APGEApogee TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$100.00 ➝ $115.007/2/2025APGEApogee TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$116.006/16/2025VCELVericelStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$67.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$15.92 per shareN/ACURLFCuraleaf$1.34B1.18$0.20 per share11.83$1.51 per share1.56PFNXPfenexN/AN/AN/AN/AN/AN/AVCELVericel$237.22M6.68$0.31 per share102.98$5.92 per share5.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$182.15M-$4.13N/AN/AN/AN/A-34.65%-32.76%11/11/2025 (Estimated)CURLFCuraleaf-$215.42M-$0.32N/AN/AN/A-18.08%-14.61%-4.47%N/APFNXPfenexN/AN/A0.00∞N/AN/AN/AN/AN/AVCELVericel$10.36M$0.12261.8671.41N/A2.85%2.47%1.69%11/6/2025 (Estimated)Latest PFNX, CURLF, APGE, and VCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025APGEApogee Therapeutics-$1.03-$1.13-$0.10-$1.13N/AN/A8/6/2025Q2 2025CURLFCuraleaf-$0.07-$0.06+$0.01-$0.07N/AN/A7/31/2025Q2 2025VCELVericel-$0.04-$0.01+$0.03-$0.01$64.61 million$63.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/ACURLFCuraleafN/AN/AN/AN/AN/APFNXPfenexN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A16.3616.36CURLFCuraleaf1.001.470.70PFNXPfenexN/AN/AN/AVCELVericelN/A4.974.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%CURLFCuraleaf0.03%PFNXPfenexN/AVCELVericelN/AInsider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics42.77%CURLFCuraleafN/APFNXPfenexN/AVCELVericel7.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9146.11 million26.39 millionOptionableCURLFCuraleaf5,519670.46 millionN/ANot OptionablePFNXPfenex7134.30 millionN/ANot OptionableVCELVericel30050.46 million46.83 millionOptionablePFNX, CURLF, APGE, and VCEL HeadlinesRecent News About These CompaniesVericel Corporation (NASDAQ:VCEL) Given Average Recommendation of "Buy" by Brokerages2 hours ago | marketbeat.comVericel (NASDAQ:VCEL) Shares Down 5.8% - Here's WhySeptember 12, 2025 | marketbeat.comHere’s Why Vericel Corp. (VCEL) Traded Down in Q2September 12, 2025 | msn.comJacobs Levy Equity Management Inc. Purchases Shares of 62,938 Vericel Corporation $VCELSeptember 12, 2025 | marketbeat.comIs the Options Market Predicting a Spike in Vericel Stock?September 11, 2025 | zacks.comVericel (NASDAQ:VCEL) Reaches New 52-Week Low - Should You Sell?September 10, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Sells 25,600 Shares of Vericel Corporation $VCELSeptember 10, 2025 | marketbeat.comRoyal Bank of Canada Boosts Stock Holdings in Vericel Corporation $VCELSeptember 8, 2025 | marketbeat.comTrexquant Investment LP Sells 57,615 Shares of Vericel Corporation $VCELSeptember 8, 2025 | marketbeat.comVericel’s Phase 3 Study on MACI: A Potential Game-Changer in Cartilage RepairSeptember 7, 2025 | tipranks.comVericel Corporation $VCEL Shares Bought by PDT Partners LLCSeptember 5, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Invests $723,000 in Vericel Corporation $VCELSeptember 3, 2025 | marketbeat.com9,769 Shares in Vericel Corporation $VCEL Bought by Jump Financial LLCSeptember 3, 2025 | marketbeat.comVericel Corporation $VCEL Stock Position Decreased by Raymond James Financial Inc.August 31, 2025 | marketbeat.comNext Century Growth Investors LLC Boosts Stock Position in Vericel Corporation $VCELAugust 30, 2025 | marketbeat.comChamplain Investment Partners LLC Lowers Stock Position in Vericel Corporation $VCELAugust 30, 2025 | marketbeat.comVericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025August 28, 2025 | markets.businessinsider.comVericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025August 28, 2025 | globenewswire.comNuveen LLC Purchases New Position in Vericel Corporation $VCELAugust 28, 2025 | marketbeat.comWellington Management Group LLP Acquires 74,723 Shares of Vericel Corporation $VCELAugust 25, 2025 | marketbeat.comRussell Investments Group Ltd. Buys 31,635 Shares of Vericel Corporation $VCELAugust 25, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePFNX, CURLF, APGE, and VCEL Company DescriptionsApogee Therapeutics NASDAQ:APGE$36.86 -0.02 (-0.05%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$37.04 +0.19 (+0.50%) As of 09/15/2025 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Curaleaf OTCMKTS:CURLF$2.36 -0.05 (-1.87%) As of 09/15/2025 03:59 PM EasternCuraleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.Pfenex NYSEAMERICAN:PFNX$12.75 0.00 (0.00%) As of 10/1/2020Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.Vericel NASDAQ:VCEL$31.42 -0.76 (-2.36%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$31.42 -0.01 (-0.02%) As of 06:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
